MHRP last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva®, administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.
The National Agency for the Control of AIDS (NACA) in Nigeria launched new consolidated service delivery guidelines on HIV and sexually transmitted infections (STIs) for key populations in Nigeria.
A recent study led by MHRP researchers showed elevated B cell immune interactions with the envelope glycoprotein (Env) on the surface of HIV during the first month of HIV infection predict the development of broadly neutralizing antibodies (bNAbs) years later.
